8-K: Alaunos Therapeutics Announces 1-for-15 Reverse Stock Split

Alaunos Therapeutics will implement a 1-for-15 reverse stock split effective January 31, 2024, to maintain Nasdaq listing compliance.

Summary

• Alaunos Therapeutics' Board of Directors approved a 1-for-15 reverse stock split of the company's common stock.
• The reverse stock split will be effective on January 31, 2024, at 5:00 p.m. Eastern Time.
• Every 15 shares of existing common stock will be combined into 1 share of common stock.
• Trading on a split-adjusted basis will begin on February 1, 2024, under the same ticker symbol TCRT but with a new CUSIP number, 98973P200.
• The reverse stock split was approved by stockholders at the Annual Meeting on June 6, 2023, with the board having discretion to set the ratio between 1-for-5 and 1-for-15.
• The final ratio of 1-for-15 was approved by the Board on January 12, 2024.
• Equiniti Trust Company is the exchange agent and will provide instructions to stockholders for exchanging pre-split shares for post-split shares.
• Fractional shares will not be issued; instead, shareholders will receive cash equal to the fraction multiplied by the closing price on the day before the effective time.

Sentiment

Score: 5

Explanation: The document is neutral in tone, detailing a necessary corporate action. While a reverse stock split can be a sign of financial challenges, it is a common practice to maintain listing compliance. The sentiment is therefore neither overly positive nor negative.

Positives

• The reverse stock split is a step to maintain compliance with Nasdaq listing requirements.
• The company has secured stockholder approval for the reverse stock split, indicating shareholder support.
• The company has engaged an exchange agent to facilitate the process for shareholders.

Negatives

• A reverse stock split can sometimes be perceived negatively by investors as it can indicate a struggling share price.
• The reverse stock split will reduce the number of outstanding shares, which may impact trading volume.

Risks

• The reverse stock split may not be sufficient to maintain long-term compliance with Nasdaq listing requirements.
• The market may react negatively to the reverse stock split, potentially leading to a decrease in share price.
• There is a risk of confusion among shareholders regarding the exchange process.

Future Outlook

The company will continue to trade on the Nasdaq Capital Market under the symbol TCRT on a split-adjusted basis starting February 1, 2024.

Management Comments

• The Board of Directors approved the filing of the Charter Amendment to effect the reverse stock split.

Industry Context

Reverse stock splits are a common mechanism for companies to regain compliance with stock exchange listing requirements, particularly when their share price has fallen below the minimum threshold. This action is not uncommon in the biotechnology sector where companies can experience significant volatility.

Comparison to Industry Standards

• Many small-cap biotech companies have used reverse stock splits to maintain their listing on exchanges like Nasdaq.
• For example, companies like Agenus Inc. and Cellectar Biosciences have also implemented reverse stock splits in the past to meet minimum share price requirements.
• The 1-for-15 ratio is within the typical range for reverse stock splits, which can vary from 1-for-2 to 1-for-20 or more.

Corporate Governance

Stakeholder Impact

• Shareholders will have their number of shares reduced by a factor of 15, but the value of their holdings should remain relatively constant immediately after the split.
• The reverse stock split is intended to maintain the company's listing on the Nasdaq, which is important for investor confidence.

Next Steps

• Shareholders will receive instructions from Equiniti Trust Company on how to exchange their pre-split shares for post-split shares.
• The company will begin trading on a split-adjusted basis on February 1, 2024.

Key Dates

Keywords

reverse stock split, Alaunos Therapeutics, TCRT, Nasdaq, stock split, share consolidation, Equiniti Trust Company, CUSIP number